Ionis wins first-ever FDA approval for Alexander disease therapy on September 04, 2026 Alexander Disease Approved Glial Fibrillary Acidic Protein Ionis Pharmaceuticals neurology pipeline Rare Diseases Recordati RNA-targeted therapy United States Food and Drug Administration Zanvastro Zilganersen +
Recordati licenses Ionis drug on June 26, 2026 Alexander Disease BARDA funding cut Ionis Norovirus Recordati Vaccines Vaxart Zilganersen +
Ionis Heads to FDA as Antisense Therapy Aces Pivotal Study in Rare Neurological Disease on September 23, 2025 Alexander Disease Antisense Oligonucleotides Fast Track Identifier Infrequent Ionis Pharmaceuticals nervous system disorder Phase I – III study United States Food and Drug Administration Zilganersen +